AzTrials
AzTrials

Melanoma (Skin)SAFESTNCT05982600

Safety and Avoidance of Futile Excisions Through Skin Tele-triage

An observational study of Melanoma (Skin) and Telemedicine, run by Herlev Hospital at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are: What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Melanoma (Skin), Telemedicine
What is being tested?
Single Assessor Teledermatological triage (TDT), 2 people Teledermatological triage (TDT) and 3 people Teledermatological triage (TDT)
How many people
5 participants
Where
1 siteDenmark
Study dates
1 Sep 2023to 24 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 250 retrospectively randomly selected patients referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma in the period between May 1st and December 31st 2022.

Who may be able to join

  • Referred to the Department of Plastic Surgery at Herlev Hospital because of suspicion of melanoma
  • Clinical and dermoscopic images registered in Dermloop
  • Histopathological diagnosis available for the lesion

Who cannot join

  • The patient's images cannot be anonymized adequately

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Gustav Gede Nervil

    Brønshøj, Copenhagen, 2700

Other trials in Denmark

About this study

Official title: Effect of Teledermoscopic Triage on Clinical Management of Skin Lesions Suspected of Melanoma

The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma. The main question[s] it aims to answer are:

  • What is the rate of correct patient management by a single, 2, 3 and 5 dermatologists.
  • What is the consequence for the patients if teledermoscopic triage is implemented, in termes of missed melanomas and reduced unnecessary excisions/biopsies.
Read more

Retrospectively included patients will have their skin lesions re-examined by setups of 1, 2, 3 and 5 tele-dermoscopists who will assign a tentative diagnosis and a recommended clinical action.

The investigators will compare the rate of correct patient management between the different setups.

Read the detailed description

Background The incidence of melanoma has been increasing in Denmark for decades [1]. With an age-standardized rate of 29.7 per 100.000 citizens, Denmark has the third highest melanoma rate in the world, and the highest rate for women (33.6) [2].

The excision rate in Danish departments of plastic surgery is close to 100%, although only 46% of referred patients have a malignant tumour [3].

To combat this over-treatment, the patient should be triaged by an expert in evaluation of skin tumours as early as possible, who, to a higher degree, could be able to distinguish between benign and malignant skin lesions and dismiss patients with benign lesions without a biopsy.

This triage should therefore be made by subspecialized dermatologists with expertise regarding diagnosing melanocytic skin lesions.

Teledermoscopy has a high sensitivity equal to face-to-face examination [8], and images taken in the primary care setting and at the hospital have been found to be of comparable quality [9], enabling an accurate assessment of images acquired in the primary care setting.

Our hypothesis is that a mandatory teledermoscopic triage by teledermoscopic experts for all pigmented lesions referred for excision, may reduce the number of unnecessary benign excisions. Yet even the experts may misdiagnose these tricky lesions, and so this study aims to evaluate the management and diagnostic values of a teledermoscopic expert panel on a high-incidence dataset and the safety of the triage method before potential clinical implementation.

Methods Based on a sample size calculation (see Statistics), 250 consecutive patients from the dataset will be included. The patients, whose skin lesions are included in the study, have been referred from PCPs or departments of dermatology at the local public hospitals, but the majority were referred by privately practicing dermatologists.

The teledermatological experts included in this study are dermatologists working mainly with diagnosing melanoma, who have more than 10 years of clinical dermatology experience and have clinical experience with teledermoscopy of melanocytic skin lesions.

Patient and lesion data and images are obtained from the electronic medical record systems Dermloop (Melatech ApS) and Sundhedsplatformen (Epic Systems), used at the Department of Plastic Surgery, Herlev and Gentofte Hospital.

The panel of tele-dermatologists will review all cases and determine a diagnosis and a management. To be able to distinguish primary and secondary outcomes, both a diagnosis and recommended clinical management are required from the experts.

Outcomes The primary outcome of the study is the recommended clinical management, Triage Values, of the TDT panels. The recommended clinical management for each lesion is assessed in binary classification of correct vs incorrect by a list of pre-defined "best practice management" rules based on its histopathological diagnosis outlined in Table 3.

Both a Majority Consensus and a Worst-Case analysis (see Statistics for further explanation) will be done.

In addition, the investigators will report the number of each management option recommended by the different modes of tele-dermatological assessment (single assessor, 2, 3 and 5 assessors).

Secondary outcomes include assessing the diagnostic values (in terms of Sensitivity, Specificity, False Negative and False Positive Rate using the dichotomized histopathological diagnosis of benign vs malignant as Gold Standard) of the TDT expert panel.

The diagnostic accuracy and range are reported separately. For the melanomas in the dataset, a descriptive analysis will me made of how often the tele-dermatologists correctly identify the Breslow thickness, in terms of true positives for each category.

Statistical analysis and Sample Size Calculation In order to discern a disparity between the conventional practice and the diagnostic efficacy of teledermatological assessment, a sample size of 44 cases is sufficient to detect a statistically significant difference, with a level of significance set at 0.05, accompanied by a statistical power of 80%. However, when evaluating the safety of a pure teledermatological triage system, it is imperative to ensure a sufficiently high sensitivity to avoid overlooking melanomas, while concurrently achieving a narrow confidence interval to confidently articulate the findings.

Based on a simulation model using R Studio [16] of five teledermoscopy experts diagnosing a number of cases with a 40% prevalence of malignancy with a sensitivity and specificity estimated from previous studies [8, 17] an estimated sensitivity of 99% can be found with a narrow confidence interval from 99%-100% with five experts evaluating 250 patient cases. Choosing an uneven number of experts for the panel enables a Majority Consensus analysis and easier interpretation of the results in regard to clinical practice.

Management is ranked hierarchically when defining "worst case" as follows, from least to worst: Dismiss, Dermatological Treatment, Followup, Biopsy, Excision.

Because incongruence between the experts is inevitable, separate analyses will be made using 1) majority consensus (ignoring answers given by less than half of the panel) and 2) "worst-case" consensus (letting even a single expert's suspicion of malignancy or recommendation for a management of a higher rank overrule the rest of the panel).

Perspective This study will report the number of patients that could have avoided having their skin lesions excised and to what degree malignant skin lesions would have been incorrectly managed if the teledermoscopically recommended clinical management had been followed.

The knowledge gained from this study has the potential to significantly change how to diagnose and triage patients suspected of having melanoma, which is the most common type of cancer among young Danes aged 15-34 [18].

The results of this and future studies will lead to the excision and treatment of fewer benign skin lesions and pave the way for a smoother patient pathway with less physical referrals, which will benefit not only patients but also lead to potential savings for the healthcare system resources by reducing the number of unnecessary consultations and procedures.

Being tested
Single Assessor Teledermatological triage (TDT), 2 people Teledermatological triage (TDT), 3 people Teledermatological triage (TDT), 5 people Teledermatological triage (TDT)
Keywords
Teledermoscopy, Melanoma, Pigmented Skin Lesions, Telemedicine
Medical subject headings
Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Single Assessor Teledermatological triage (TDT)Diagnostic test

    Also called Single Assessor

    The skin lesion is assessed, diagnosed and triaged by one dermatologist assessors.

  • 2 people Teledermatological triage (TDT)Diagnostic test

    Also called 2 people assessment

    The skin lesion is assessed, diagnosed and triaged by 2 dermatologist assessors. Worst case overrules.

  • 3 people Teledermatological triage (TDT)Diagnostic test

    Also called 3 people assessment

    The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.

  • 5 people Teledermatological triage (TDT)Diagnostic test

    Also called 5 people assessment

    The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.

Study groups in NCT05982600
Study groupRoleWhat they receive
Cancer Pathway referred patientPatient referred for assessment and excision of their skin lesion, because of a suspicion of melanoma by the referring doctor.
Receives: Diagnostic Test: Single Assessor Teledermatological triage (TDT); Diagnostic Test: 2 people Teledermatological triage (TDT); Diagnostic Test: 3 people Teledermatological triage (TDT); Diagnostic Test: 5 people Teledermatological triage (TDT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Triage Values

    Recommended clinical action, correct vs incorrect. Each teledermatologist will recommend a clinical action for each patient case. We evaluate the correctness of this recommended clinical action (in binary classification of correct vs incorrect) by a list of pre-defined "best practice management rules" for each diagnosis.

    Measured: Immediately after all participants have completed the evaluations

Secondary outcomes (1)
  1. Diagnostic Values

    Secondary outcomes include assessing the diagnostic values (in terms of Sensitivity, Specificity, False Negative and False Positive Rate using the dichotomized histopathological diagnosis of benign vs malignant as Gold Standard) of the TDT expert panel.

    Measured: Immediately after all participants have completed the evaluations

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2023
  2. Study start1 Sep 2023
  3. Primary completion31 Dec 2023
  4. Study completion24 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
5 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05982600
Sponsor's protocol ID
SAFEST Trial
Acronym
SAFEST
Status last verified
Oct 2024
First submitted
24 Jul 2023
Last updated
8 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Sample-size simulation codes, data-analysis codes and deidentified data will be shared through data repository.

Questions about this trial

What is this clinical trial studying?

An observational study of Melanoma (Skin) and Telemedicine, run by Herlev Hospital at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Triage Values (time frame: Immediately after all participants have completed the evaluations). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in